ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Wednesday, October 29, 2025

10:15AM-10:30AM: Abstract Number: 2654

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)

10:15AM-10:30AM: Abstract Number: 2642

Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study

Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)

10:15AM-10:30AM: Abstract Number: 2648

Transcriptome analysis of quiescent SLE cases uncovers dysregulated pathways associated with disease flares

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

10:30AM-10:45AM: Abstract Number: 2655

Fetal and maternal outcomes in systemic sclerosis and very early diagnosis of systemic sclerosis pregnancies, a national prospective study

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)

10:30AM-10:45AM: Abstract Number: 2643

Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy

Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)

10:30AM-10:45AM: Abstract Number: 2649

Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

10:45AM-11:00AM: Abstract Number: 2650

LFA-REAL Outperforms SLEDAI and BILAG in Detecting Clinical Change in Lupus Activity

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

10:45AM-11:00AM: Abstract Number: 2656

Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)

10:45AM-11:00AM: Abstract Number: 2644

Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients

Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)

11:30AM-11:45AM: Abstract Number: 2693

CAR T-cell Therapy in SLE: A Systematic Review

Abstracts: Systemic Lupus Erythematosus – Treatment II (2693–2698)

11:30AM-11:45AM: Abstract Number: 2699

Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II (2699–2704)

11:30AM-11:45AM: Abstract Number: 2681

Derivation and Validation of Inflammation-Adjusted Lipid Measures to Improve Cardiovascular Risk Prediction in Rheumatoid Arthritis

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes III: Long Live (Comorbidity and Outcomes) (2681–2686)

11:30AM-11:45AM: Abstract Number: 2687

Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Pathogenesis, Exercise, and Dietary Interventions (2687–2692)

11:30AM-11:45AM: Abstract Number: 2657

Incidence of Rheumatic Diseases Among Patients Receiving GLP-1 Receptor Agonists: A Comparative Analysis with DPP-4 Inhibitors in a Propensity Score-Matched Cohort

Abstracts: Epidemiology & Public Health I (2657–2662)

11:30AM-11:45AM: Abstract Number: 2663

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].